Evidence suggests inflammatory bowel disease is equally prevalent in transgender and cisgender populations. However, it remains unclear whether gender-affirming care and the higher rates of trauma experienced by many transgender patients affect disease course.As political pressure threatens access to gender-affirming hormone therapy (GAHT), patients with IBD who are transgender are increasingly